Developer docs
API playgroundTry for free, no card

Search company profiles

Sanofi China

Full company profile

uuid000i34u

Namestring
Sanofi China
Legal namestring
赛诺菲(中国)投资有限公司
Websiteurl
sanofi.cn
Company typeenum
Public
Founded yearint
1982
Descriptiontext

Sanofi China is the local operating subsidiary of Sanofi S.A. (EPA:SAN), the Paris-headquartered global biopharmaceutical company, and has been present in the Chinese market since 1982. The subsidiary conducts research and development, manufacturing, and commercialization of innovative therapeutic products across immunology, oncology, cardiovascular disease, rare diseases, vaccines, and diabetes. Its footprint includes the Shanghai regional headquarters, a Beijing R&D center with 230+ staff covering regulatory affairs, development, and global operations, the Suzhou Global Research Institute focused on early-stage oncology and immuno-inflammation research, the Beijing insulin production base (Sanofi's largest in Asia-Pacific), and the Chengdu Innovation and Operations Center that opened in March 2026.

The company operates an AI-enabled R&D platform and digital commercial systems, applying predictive analytics to drug safety and using AI to accelerate compound development across therapeutic areas. The technology stack integrates immunoscience expertise with data platforms for drug discovery, clinical development, and omnichannel customer engagement in China. Product offerings span prescription drugs, vaccines (including pediatric, flu, RSV, and travel), and insulin pens manufactured domestically.

Commercially, Sanofi China runs a direct field sales model targeting hospitals and medical institutions, with district managers and medical information communication representatives organized by therapeutic area, alongside pharmacy distribution and government partnerships for national immunization programs. Revenue streams are diversified across pharmaceutical products, vaccines, and insulin/diabetes care, with pricing determined by government-negotiated reimbursement and prescription channels rather than disclosed enterprise contracts. The subsidiary has been ranked the #1 Top Employer in China for six consecutive years (2021-2026) and has been recognized by the World Economic Forum as a Skills Lighthouse institution.

Short descriptiontext

Sanofi China is the Shanghai-incorporated subsidiary of Sanofi S.A., operating since 1982 in the research, development, manufacturing, and commercialization of innovative medicines and vaccines across immunology, oncology, cardiovascular, rare diseases, vaccines, and diabetes for the Chinese market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical products, vaccine development, biopharmaceutical R&D, insulin manufacturing, immunology therapeutics
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical products
TypeOne Time License
Description

Revenue from prescription drugs across multiple therapeutic areas including immunology, cardiovascular, oncology, and rare diseases.

jobs.sanofi.cn
2Vaccines
TypeOne Time License
Description

Revenue from vaccine products including pediatric vaccines, travel vaccines, and seasonal vaccines like flu and RSV prevention.

jobs.sanofi.cn
3Insulin and diabetes care
TypeOne Time License
Description

Revenue from insulin products manufactured at the Beijing production base, serving the Asia-Pacific region.

jobs.sanofi.cn
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sanofi China researches, develops, manufactures, and markets innovative pharmaceutical products and vaccines in China, spanning therapeutic areas such as immunology, cardiovascular, oncology, rare diseases, and diabetes care. Core offerings include a vaccines portfolio (pediatric, flu, RSV, and travel vaccines), insulin injection pens manufactured in Beijing for the Asia-Pacific market, and specialty prescription drugs for immune-mediated, rare, and serious diseases. The company supports its portfolio with AI-powered R&D, an immunoscience platform, and a field sales force targeting hospitals, medical institutions, and government vaccination programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 40+ innovative drugs and vaccines brought to China since 1982, treating 70% of life-threatening serious diseases
+2 more records
Product and service6 records
1Vaccines portfolio (Sanofi Vaccines China)
CategoryVaccines
Description

Sanofi's vaccines portfolio for the China market, covering pediatric, seasonal (flu), travel, and specialty vaccines, distributed via hospitals, pharmacies, and government public health programs.

2Insulin injection pens (Sanofi Beijing insulin production)
CategoryDiabetes care / insulin therapeutics
Description

Insulin injection pens and diabetes care products manufactured at Sanofi's Beijing production base, serving the Asia-Pacific region. The Beijing facility is Sanofi's largest insulin production center in the region.

3Prescription pharmaceuticals (Sanofi China specialty medicines)
CategorySpecialty prescription pharmaceuticals
Description

Sanofi's prescription pharmaceutical portfolio sold in China, covering immunology, cardiovascular, oncology, rare diseases, blood disorders, and neurological disorders for hospitals, physicians, and patients.

4Beyfortus (RSV vaccine for infants)
CategoryVaccines
Description

Beyfortus is Sanofi's RSV (respiratory syncytial virus) prevention product for infants, positioned as a breakthrough in the pediatric vaccines portfolio.

5Aficamten (cardiac myosin inhibitor for hypertrophic cardiomyopathy)
CategoryCardiovascular therapeutics
Description

Aficamten is a cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy; in-licensed for the Greater China market through a partnership with Ji Xing.

6Plozasiran Sodium Injection (普乐司兰钠注射液)
CategoryCardiovascular therapeutics
Description

Plozasiran Sodium Injection is an investigational nucleic acid drug for cardiovascular/lipid diseases, licensed in to Sanofi for the Greater China market from a Viatris subsidiary.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Sanofi obtained Greater China rights for Viatris subsidiary's investigational drug Pulsi Lanna sodium injection (普乐司兰钠注射液).

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-12-20
Description

Sanofi and Ji Xing announced agreement for Aficamten in Greater China market. Ji Xing develops and commercializes cardiovascular innovative drugs in China, with Sanofi gaining rights for this therapeutic candidate in the Greater China region.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-25
Description

Dermatology and immunology care initiative celebrating China-France health cooperation for children, part of Sanofi's commitment to China-France healthcare exchange.

4Shanghai Soong Ching Ling Foundation (上海宋庆龄基金会)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-22
Description

Sanofi partnered with Shanghai Soong Ching Ling Foundation to launch youth health awareness and education program, supporting adolescent health education initiatives.

sanofi.cn
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novartis China is a comparable multinational innovator pharma subsidiary with overlapping therapeutic areas in cardiovascular, immunology, and rare diseases. Both rely heavily on NRDL inclusion and hospital channel sales forces.

TypeDirect peer
Description

J&J Innovative Medicine China competes with Sanofi in immunology, oncology, and rare disease therapeutic areas. Both operate specialty sales models targeting hospital specialists and key opinion leaders.

3Eli Lilly China
TypeDirect peer
Description

Eli Lilly China is a comparable multinational pharmaceutical subsidiary with significant overlap in diabetes (insulin and beyond) and immunology therapeutic areas. Both compete directly in the insulin manufacturing space in China.

TypeDirect peer
Description

Pfizer operates a similar multinational pharmaceutical subsidiary in China with a comparable therapeutic focus spanning vaccines, oncology, rare diseases, and primary care. Both compete directly for hospital channel access, NRDL inclusion, and physician engagement.

TypeDirect peer
Description

AstraZeneca China is one of Sanofi's closest peers in cardiovascular, respiratory, and oncology in China, with similar reliance on NRDL inclusion and large field sales organizations. AstraZeneca is the largest multinational pharma player in China by revenue, setting competitive benchmarks.

TypeRegional player
Description

Sinopharm is a state-owned domestic Chinese pharmaceutical distributor and manufacturer that competes with Sanofi primarily in vaccine distribution, government immunization programs, and pharmaceutical wholesale channels in the China market.

TypeDirect peer
Description

AbbVie China competes with Sanofi in immunology (Humira biosimilar competition, Skyrizi/Rinvoq positioning) and oncology. Both rely on specialty pharmacy and hospital immunology channel access.

8Roche China
TypeDirect peer
Description

Roche China competes head-to-head with Sanofi in specialty pharmaceuticals, oncology, and immunology across hospital and pharmacy channels in China. Both share similar GTM models via field sales targeting hospitals and physicians.

9Merck & Co. (MSD) China
TypeDirect peer
Description

MSD China is a direct peer as a multinational pharmaceutical subsidiary with strong vaccine (HPV, pneumococcal) and oncology franchises. Both compete in hospital channel access and government vaccination program tenders.

TypeDirect peer
Description

GSK China is a direct peer in vaccines (including pediatric and travel) and specialty pharmaceuticals with a similar GTM motion targeting hospitals and government immunization programs. Both face comparable NRDL and VBP pricing dynamics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanofi China

Pharmaceuticalssanofi.cn

Sanofi China is the Shanghai-incorporated subsidiary of Sanofi S.A., operating since 1982 in the research, development, manufacturing, and commercialization of innovative medicines and vaccines across immunology, oncology, cardiovascular, rare diseases, vaccines, and diabetes for the Chinese market.

What Sanofi China does

Sanofi China is the local operating subsidiary of Sanofi S.A. (EPA:SAN), the Paris-headquartered global biopharmaceutical company, and has been present in the Chinese market since 1982. The subsidiary conducts research and development, manufacturing, and commercialization of innovative therapeutic products across immunology, oncology, cardiovascular disease, rare diseases, vaccines, and diabetes. Its footprint includes the Shanghai regional headquarters, a Beijing R&D center with 230+ staff covering regulatory affairs, development, and global operations, the Suzhou Global Research Institute focused on early-stage oncology and immuno-inflammation research, the Beijing insulin production base (Sanofi's largest in Asia-Pacific), and the Chengdu Innovation and Operations Center that opened in March 2026.

The company operates an AI-enabled R&D platform and digital commercial systems, applying predictive analytics to drug safety and using AI to accelerate compound development across therapeutic areas. The technology stack integrates immunoscience expertise with data platforms for drug discovery, clinical development, and omnichannel customer engagement in China. Product offerings span prescription drugs, vaccines (including pediatric, flu, RSV, and travel), and insulin pens manufactured domestically.

Commercially, Sanofi China runs a direct field sales model targeting hospitals and medical institutions, with district managers and medical information communication representatives organized by therapeutic area, alongside pharmacy distribution and government partnerships for national immunization programs. Revenue streams are diversified across pharmaceutical products, vaccines, and insulin/diabetes care, with pricing determined by government-negotiated reimbursement and prescription channels rather than disclosed enterprise contracts. The subsidiary has been ranked the #1 Top Employer in China for six consecutive years (2021-2026) and has been recognized by the World Economic Forum as a Skills Lighthouse institution.

Sanofi China firmographics

Firmographics
Name
Sanofi China
Legal name
赛诺菲(中国)投资有限公司
Website
https://sanofi.cn
Company type
Public
Founded year
1982
Operating status
Operating
Headcount range
11–50 employees
Short description
Sanofi China is the Shanghai-incorporated subsidiary of Sanofi S.A., operating since 1982 in the research, development, manufacturing, and commercialization of innovative medicines and vaccines across immunology, oncology, cardiovascular, rare diseases, vaccines, and diabetes for the Chinese market.
Ownership category
akta.pro rank

Sanofi China industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Pharmaceutical products
  • Vaccine development
  • Biopharmaceutical R&D
  • Insulin manufacturing
  • Immunology therapeutics

Where Sanofi China is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices5 records

Markets served

Sanofi China business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical products: Revenue from prescription drugs across multiple therapeutic areas including immunology, cardiovascular, oncology, and rare diseases.
  2. Vaccines: Revenue from vaccine products including pediatric vaccines, travel vaccines, and seasonal vaccines like flu and RSV prevention.
  3. Insulin and diabetes care: Revenue from insulin products manufactured at the Beijing production base, serving the Asia-Pacific region.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Sanofi China product offering

Product offering

Core offering

Sanofi China researches, develops, manufactures, and markets innovative pharmaceutical products and vaccines in China, spanning therapeutic areas such as immunology, cardiovascular, oncology, rare diseases, and diabetes care. Core offerings include a vaccines portfolio (pediatric, flu, RSV, and travel vaccines), insulin injection pens manufactured in Beijing for the Asia-Pacific market, and specialty prescription drugs for immune-mediated, rare, and serious diseases. The company supports its portfolio with AI-powered R&D, an immunoscience platform, and a field sales force targeting hospitals, medical institutions, and government vaccination programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vaccines portfolio (Sanofi Vaccines China) Sanofi's vaccines portfolio for the China market, covering pediatric, seasonal (flu), travel, and specialty vaccines, distributed via hospitals, pharmacies, and government public health programs.
  • Insulin injection pens (Sanofi Beijing insulin production) Insulin injection pens and diabetes care products manufactured at Sanofi's Beijing production base, serving the Asia-Pacific region. The Beijing facility is Sanofi's largest insulin production center in the region.
  • Prescription pharmaceuticals (Sanofi China specialty medicines) Sanofi's prescription pharmaceutical portfolio sold in China, covering immunology, cardiovascular, oncology, rare diseases, blood disorders, and neurological disorders for hospitals, physicians, and patients.
  • Beyfortus (RSV vaccine for infants) Beyfortus is Sanofi's RSV (respiratory syncytial virus) prevention product for infants, positioned as a breakthrough in the pediatric vaccines portfolio.
  • Aficamten (cardiac myosin inhibitor for hypertrophic cardiomyopathy) Aficamten is a cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy; in-licensed for the Greater China market through a partnership with Ji Xing.
  • Plozasiran Sodium Injection (普乐司兰钠注射液) Plozasiran Sodium Injection is an investigational nucleic acid drug for cardiovascular/lipid diseases, licensed in to Sanofi for the Greater China market from a Viatris subsidiary.

Quantifiable outcome

  • 40+ innovative drugs and vaccines brought to China since 1982, treating 70% of life-threatening serious diseases
  • +2 more outcomes

Companies that use Sanofi China

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Sanofi China technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Sanofi China partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and minor.

  • Viatris subsidiary (维亚臻)majorStrategic or Co-development Partner · 1 August 2025Sanofi obtained Greater China rights for Viatris subsidiary's investigational drug Pulsi Lanna sodium injection (普乐司兰钠注射液).
  • Ji Xing (箕星)majorStrategic or Co-development Partner · 20 December 2024Sanofi and Ji Xing announced agreement for Aficamten in Greater China market. Ji Xing develops and commercializes cardiovascular innovative drugs in China, with Sanofi gaining rights for this therapeutic candidate in the Greater China region.
  • French healthcare institutionsminorStrategic or Co-development Partner · 25 May 2024Dermatology and immunology care initiative celebrating China-France health cooperation for children, part of Sanofi's commitment to China-France healthcare exchange.
  • Shanghai Soong Ching Ling Foundation (上海宋庆龄基金会)minorStrategic or Co-development Partner · 22 March 2024Sanofi partnered with Shanghai Soong Ching Ling Foundation to launch youth health awareness and education program, supporting adolescent health education initiatives.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Sanofi China competitors and assessment

Company assessment

Direct peers

  • Novartis China: Novartis China is a comparable multinational innovator pharma subsidiary with overlapping therapeutic areas in cardiovascular, immunology, and rare diseases. Both rely heavily on NRDL inclusion and hospital channel sales forces.
  • Johnson & Johnson Innovative Medicine China: J&J Innovative Medicine China competes with Sanofi in immunology, oncology, and rare disease therapeutic areas. Both operate specialty sales models targeting hospital specialists and key opinion leaders.
  • Eli Lilly China: Eli Lilly China is a comparable multinational pharmaceutical subsidiary with significant overlap in diabetes (insulin and beyond) and immunology therapeutic areas. Both compete directly in the insulin manufacturing space in China.
  • Pfizer China: Pfizer operates a similar multinational pharmaceutical subsidiary in China with a comparable therapeutic focus spanning vaccines, oncology, rare diseases, and primary care. Both compete directly for hospital channel access, NRDL inclusion, and physician engagement.
  • AstraZeneca China: AstraZeneca China is one of Sanofi's closest peers in cardiovascular, respiratory, and oncology in China, with similar reliance on NRDL inclusion and large field sales organizations. AstraZeneca is the largest multinational pharma player in China by revenue, setting competitive benchmarks.
  • AbbVie China: AbbVie China competes with Sanofi in immunology (Humira biosimilar competition, Skyrizi/Rinvoq positioning) and oncology. Both rely on specialty pharmacy and hospital immunology channel access.
  • Roche China: Roche China competes head-to-head with Sanofi in specialty pharmaceuticals, oncology, and immunology across hospital and pharmacy channels in China. Both share similar GTM models via field sales targeting hospitals and physicians.
  • Merck & Co. (MSD) China: MSD China is a direct peer as a multinational pharmaceutical subsidiary with strong vaccine (HPV, pneumococcal) and oncology franchises. Both compete in hospital channel access and government vaccination program tenders.
  • GSK China: GSK China is a direct peer in vaccines (including pediatric and travel) and specialty pharmaceuticals with a similar GTM motion targeting hospitals and government immunization programs. Both face comparable NRDL and VBP pricing dynamics.

Regional players

  • Sinopharm Group: Sinopharm is a state-owned domestic Chinese pharmaceutical distributor and manufacturer that competes with Sanofi primarily in vaccine distribution, government immunization programs, and pharmaceutical wholesale channels in the China market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sanofi China financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanofi China leadership team

Management profile

Number of profiles

Profiles3 records

Sanofi China subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Sanofi China funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanofi China M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi China

What does Sanofi China do?

Sanofi China researches, develops, manufactures, and markets innovative pharmaceutical products and vaccines in China, spanning therapeutic areas such as immunology, cardiovascular, oncology, rare diseases, and diabetes care. Core offerings include a vaccines portfolio (pediatric, flu, RSV, and travel vaccines), insulin injection pens manufactured in Beijing for the Asia-Pacific market, and specialty prescription drugs for immune-mediated, rare, and serious diseases. The company supports its portfolio with AI-powered R&D, an immunoscience platform, and a field sales force targeting hospitals, medical institutions, and government vaccination programs.

Is Sanofi China a public or private company?

Sanofi China is a public company. It is classified as corporate owned and is currently operating.

When was Sanofi China founded?

Sanofi China was founded in 1982. It employs 11 to 50 people.

Where is Sanofi China based?

Sanofi China is headquartered in Paris, France, in the Europe region.

How does Sanofi China make money?

Three revenue lines are on record. Pharmaceutical products are the primary driver. The others are vaccines and insulin and diabetes care.

Who are Sanofi China's main competitors?

Direct peers on record are Novartis China, Johnson & Johnson Innovative Medicine China, Eli Lilly China, Pfizer China, AstraZeneca China, AbbVie China, Roche China, Merck & Co. (MSD) China and GSK China. Sinopharm Group is listed as a regional player.

Does Sanofi China have an API?

No public API is recorded for Sanofi China.

What industry is Sanofi China in?

Sanofi China's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales